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Abstract
Noncoding RNAs represent a high proportion of the human genome and 
regulate gene expression by means of innumerable and unimaginable modes of 
action. Particularly, long noncoding RNAs have emerged as central regulators of 
gene expression and alterations on their function have been associated with many 
types of cancer, such as astrocytomas. Astrocytomas are the most common type 
of gliomas in the central nervous system, and glioblastoma multiforme is their 
most aggressive form. Although adult and pediatric astrocytomas exhibit certain 
molecular similarities, they are considered as distinct molecular entities. Since to 
date there is no effective treatments for these tumors, different efforts are being 
made to find molecular tools useful for this purpose. Studies have shown that 
both tumor and circulating expression of lncRNAs were altered in astrocytoma, 
which was useful to distinguish the patients with this neoplasia from those without 
cancer, as well as to determine different prognostic factors related to the disease. 
According to these studies, different “molecular signatures” of specific lncRNAs 
were established, and they have a potential use in the medical practice. From a sys-
tem biological perspective, complex interaction networks, conformed by lncRNAs, 
microRNAs, mRNAs, and proteins, were elucidated and predicted to control many 
oncogenic processes.
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1. Introduction
Noncoding RNAs (ncRNAs) represent a significant fraction of the human 
genome [1], and the great diversity and forms of action of these RNA species 
has put them at the center of biomedical research of diseases, such as cancer 
[2–4]. LncRNAs are not the exception, and many of them have been proposed as 
possible diagnostic and prognostic biomarkers for Ast [5]. LncRNAs are RNAs 
of more than >200 nucleotides in length, which have to meet certain additional 
criteria to be classified within this category [6]. The evolutionary conservation 
of lncRNAs among species is poor [7], and they are transcribed by a variety 
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of transcriptional mechanisms [6]. Many cellular processes are regulated by 
lncRNAs and this could be at both cytoplasmic and nuclear levels, as well as dis-
tance by moving them to their target tissues through different bodily fluids, such 
as blood [8]. LncRNAs exert their functions by establishing interactions with 
other lncRNA and RNA species, as well as with proteins [9], and changes on their 
functioning have been associated with cancer and particularly with astrocytomas 
(Ast) [5].
Gliomas represent 81% of the Central Nervous System (CNS) tumors of which 
the most common subtypes in adults are glioblastoma multiforme (GBM), ana-
plastic Ast (AAst), and oligodendrogliomas [10, 11]. In the pediatric counterpart, 
pilocytic Ast (PAst) is the most common type in pediatric age [11]. According to 
the new classification of the World Health Organization (WHO), Ast are now 
classified according to the presence or absence of IDH1/IDH2 mutations, as well as 
by phenotypic traits and integral diagnoses [12]. Those tumors with IDH1/IDH2 
mutations were classified as “diffuse gliomas,” a new group that includes diffuse Ast 
(DAst; Grade II), AAst (Grade III), GBM, and diffuse oligodendrogliomas (Grade 
I and II) [12]. Meanwhile, pilocytic Ast (PAst; Grade I), subependymal giant cells 
Ast (Grade I), and pleomorphic xanthoastrocytoma (Grade II) were excluded from 
the diffuse group, given that they do not have these mutations [12]. Although there 
are certain molecular similarities between adult and pediatric Ast (p-Ast) [13], 
their molecular differences are well established and based on this, they are clas-
sified as different tumor subtypes [14–17]. Although there have been advances in 
the Ast study—mainly on adult GBM—, to date, there are very few molecular tools 
useful for Ast diagnosis, prognosis, and treatment. Essentially, most studies have 
identified changes on the expression of lncRNAs in both tumor tissues and GBM 
cell lines, and according to this, some “molecular signatures” have been postulated 
for the diagnosis and prognosis of Ast. For instance, circulating lncRNAs have 
allowed the distinction of patients sensitive or resistant to treatments, specifically 
to temozolomide (TMZ) or radiotherapy [18, 19]. In addition, the establishment 
of bioinformatic algorithms identified interactome networks in which lncRNAs 
physically interact with other lncRNAs, as well as with messenger RNAs (mRNAs) 
and microRNAs (miRNAs), and proteins. These studies have shown that expres-
sion changes of lncRNAs could lead to the amplification of the aberrant signals, 
which in turn could lead to alterations of many signaling pathways and cellular 
processes [5, 20, 21]. In p-Ast, high expression levels of LINC-ROR (long intergenic 
nonprotein coding RNA, regulator of reprogramming) were useful to distinguish 
p-Ast from the control, as well as to identify the GBM from the rest of the Ast 
grades; this strongly suggests the involvement of LINC-ROR in p-Ast diagnosis and 
prognosis [5].
2. Astrocytoma
Although the new WHO classification of tumors of the CNS takes into account 
phenotypic traits, it also takes into account other criteria, such as the genotype and 
integral diagnoses of the disease [12]. According to this classification, Ast are now 
classified mainly by the presence or absence of IDH1/IDH2 mutations and based on 
this, diffuse Ast (DAst; Grade II) and anaplastic Ast (AAst; Grade III), as well as the 
GBM, and diffuse oligodendrogliomas (Grade I and II) were classified as “diffuse 
gliomas“ [12]. PAst, subependymal giant cells Ast, and pleomorphic xanthoastro-
cytoma (Grade II) were classified in a different group, because of the absence of 
IDH1/IDH2 mutations.
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2.1 Astrocytomas that lack IDH1 and IDH2 mutations
These tumors have a well circumscribed growth pattern, lack IDH alterations, 
and they frequently have BRAF (pilocytic Ast (Past) and pleomorphic xanthoastro-
cytoma) and TSC1/TSC2 mutations (subependymal giant cells Ast) (Table 1).
PAst are the most common type of Ast in pediatric age and are characterized by 
their biphasic pattern: compact bipolar cells with Rosenthal fibers, microquistes, 
and granular bodies (Figure 1A). As a general rule, PAst are well-defined tumors 
Table 1. 
Astrocytoma classification according to the World Health Organization (2016).
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(Figure 2A); so they can be surgically resected without causing damage to the 
adjacent tissue and they do not progress to more aggressive stages; therefore, PAst 
are considered as neoplasms of good prognosis.
PAst are developed along the neuroaxis, and they are preferably located in the 
cerebellum [22–24]. It is important to mention that there are genetic diseases such as 
neurofibromatosis 1 (NF-1), which influences the formation of PAst; approximately 
15% of individuals with NF-1 develop these type of tumors, specifically at the level 
of the optic nerve [25, 26].
2.2 Diffuse gliomas (tumors with IDH1 and IDH2 mutations)
In the previous WHO classification, diffuse Ast (DAst) were classified as an 
independent group, but now they are classified along with anaplastic Ast (Aast; 
Grade III) and glioblastoma (GBM; Grade IV) (Figures 1B–D and 2B–D), as well 
as with diffuse oligodendrogliomas (Grade I and II) [12]. Although factors such 
as growth and tumor behavior are still taken into account, the feature that distin-
guishes them as diffuse gliomas are the IDH1 and IDH2 mutations; however, these 
tumors can be subclassified into the IDH-mutant, IDH-wildtype, and NOS catego-
ries [12].
IDH-wildtype neoplasms constitute a subgroup of uncommon tumors, which 
are negative for mutant R132H IDH1 protein and genic mutations for IDH1 (codon 
132) and IDH2 (codon 172). Importantly, DAst (WHO Grade II) and AAst (WHO 
Grade III) can be confused with gangliogliomas and IDH-wildtype GBM [27, 28]. 
Figure 1. 
(A) Pilocytic Ast. Photomicrograph that shows a glioma with astrocytes, which have an elongated cytoplasm 
and a pilocytic appearance, on a loose stroma (H&E, 40×). (B) Diffuse astrocytoma. Diffuse glioma with cysts 
and solid areas; the cells are homogenous and do not exhibit atypia (H&E, 40×). (C) Anaplastic astrocytoma. 
Neoplasia with hypercellularity and nuclear pleomorphism and hyperchromatism. In the upper left, a blood 
vessel with a glomerular pattern can be seen (H&E, 40×). (D) GBM. Hypercellular glial tumor with diffuse 
pleomorphism and necrosis; it is delimitated by palisaded cells, which are characteristic of GBM (H&E, 10×). 
Photomicrographs taken at the pediatric Pathology Service of the Children’s Hospital, National Medical Center 
Century XXI, IMSS.
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Tumors that do not have any of these molecular tests—immunohistochemistry or 
sequencing—are subclassified as DAst-NOS or AAst-NOS, respectively [12].
2.2.1 Glioblastoma
According to the new WHO classification, the GBM was also classified into the 
group of diffuse gliomas and subclassified into the IDH-mutant or IDH-wildtype 
categories, or the NOS category. The IDH-wildtype form represents ~90% of cases 
and was associated with primary GBM (de novo), which are more common in 
patients older than 55 years of age [29]. Meanwhile, the IDH-mutant GBMs (~10%) 
are tumors that develop from low-grade diffuse glioma and are commonly present in 
younger patients; this type of GBM are also known as secondary GBM [29]. Similar 
to that described above, GBM-NOS are those tumors that do not have a full IDH 
evaluation [12]. According to phenotypic traits and the genetic background, to date, 
there are different GBM variants (Table 1).
Figure 2. 
(A and B) Pilocytic and diffuse astrocytoma. These tumors are both isodense and hypodense to the brain and 
show calcifications in 15–20% of cases, and they have virtually no edema. (C) Anaplastic astrocytoma is 
poorly defined lesions with heterogenous signal strengths. Mixed areas of isodensity to hipodensity are observed; 
these tumors may have hemorrhagic foci. It is common to observe a hypertensive central nucleus, which is 
surrounded by an intense edge with peripheral finger-like projections and secondary to a vasogenic edema. 
(D) GBM. Heterogenous lesion with cellular components of mixed signal, central necrosis, and hemorrhage; 
calcifications are rare.
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2.3 Pediatric diffuse gliomas
Pediatric diffuse gliomas have the K27 mutation in the gene H3F3A (H3 Histone 
Family Member 3A) and less commonly in the related gene HIST1H3B (Histone 
Cluster 1 H3 Family Member B). Although they are mainly present in children, 
they can also be present in adults. These tumors exhibit a diffuse growth pattern 
and a midline location: thalamus, brain stem, and spinal cord; therefore, they are 
classified as diffuse midline glioma, H3 K27 mutant, and include tumors previously 
known as diffuse intrinsic pontine glioma (DIPG) [12].
3. LncRNAs in astrocytoma
LncRNAs have emerged as important molecular elements in different types 
of cancer, and Ast are not the exception [5, 30–32]. To date, diverse studies have 
shown the high complexity of the lncRNA study in Ast, due to the wide variety of 
mechanisms by which lncRNAs exerts their biological actions and because of the 
high tumor heterogeneity [33–35]. Changes in the nucleotide sequence of lncRNAs, 
their transcription rate, the expression of specific variants, in their expression 
levels, among others, could lead to an aberrant amplification of cell signals [36–38]. 
Given that GBM is the most aggressive type of cancer that begins within the brain 
[39, 40], most studies have been focused on this tumor subtype and to a lesser 
extent in the other WHO grades of adult Ast or in all WHO grades of p-Ast. Despite 
the significant effort that has been made in recent years to learn more about Ast, to 
the best of our knowledge, to date, there are very few molecular tools really appli-
cable to diagnose, prognose, or treatment of these tumors [41–43]. Therefore, there 
is great interest to establish these molecular tools for GBM and evidence indicates 
that lncRNAs seem to be good candidates to serve such purpose.
3.1 LncRNAs as potential astrocytoma biomarkers
Expression changes of a biomolecule are a powerful tool to establish molecular 
“signatures” or “fingerprints” useful to distinguish and identify subgroups of a 
disease with a particular clinical behavior [44–47]. In this sense, expression changes 
of lncRNAs have been useful to differentiate both adult and pediatric Ast from non-
neoplastic tissues, and some of them have the potential to be used in the medical 
practice as biomarkers. The meta-analysis performed by Zhang et al. [48] demon-
strated for the first time the usefulness of the lncRNAs aberrantly expressed for Ast 
diagnosis and prognosis. This study showed that the expression profile of lncRNAs 
allowed to differentiate Ast or oligodendrogliomas from nonneoplastic tissues and 
to associate it with Ast malignancy or with lineage distinction in gliomas (Table 2).  
Subsequently, the same group established the first “molecular signature” of 
lncRNAs for Ast diagnosis and prognosis, which distinguished this neoplasia from 
nonneoplastic tissues, as well as Ast malignancy or patient’s survival (Table 2)  
[49]. Additionally, a second group of precise lncRNAs was specific for Ast, and it 
was functional to differentiate them from the control tissues; from this signature, 
two lncRNAs were also associated with Ast malignancy, since their expression 
distinguished Ast WHO grades (Table 2) [50]. However, none of the lncRNAs that 
were part of the first molecular signature was established in the second, which 
could be related to the samples included in each study—referring to age, sex, with 
or without treatment, radiotherapy, among others—, as well as to the bioinformatic 
approach used in each study. This evidence emphasizes the importance that has the 
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homogenization of patient’s samples included in a study has and how crucial it is to 
specify the clinic features of the included patients.
In addition to changes in the lncRNA expression, their promoter methyla-
tion status seems to be useful for Ast diagnosis and prognosis. Specifically, it was 
shown that expression and the promoter methylation pattern of LOC285758 (Long 
Intergenic Non-Protein Coding RNA 1268) differentiate all Ast WHO grades and 
other gliomas (oligodendroglioma and oligoastrocitoma (II–III)) from the control, 
as well as Ast grades I–III from both primary and secondary GBM (Table 2) [32]. 
Based on this evidence, the identification of the mechanisms that lead to an aber-
rant expression of the lncRNAs—such as epigenetic regulation—could be part of 
the biomarkers package useful in the medical practice.
3.2 LncRNAs as potential GBM biomarkers
Specifically for GBM, different lncRNAs have also been found as potential 
biomarkers for its diagnosis and prognosis (Table 3). In this sense, Xu et al. [51] 
identified lncRNAs, which were associated with patient’s survival; particularly, 
high expression of SNHG1 (small nucleolar RNA host gene 1) was related with 
poor prognosis (Table 3). Meanwhile, in silico analysis showed many differentially 
expressed lncRNAs useful to distinguish GBM from nonneoplastic tissues and each 
Table 2. 
Molecular signatures of lncRNAs in astrocytoma.
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of the four GBM subtypes: classical, mesenchymal, neural, and proneural. The 
lncRNAs CRNDE (colorectal neoplasia differentially expressed) and CYTOR (cyto-
skeleton regulator RNA) (both upregulated) and TUNAR (TCL1 upstream neural 
differentiation-associated RNA) and LINCO1476 (both downregulated) were those 
with the highest expression changes in GBM compared to the control and with a 
potential use for GBM diagnosis (Table 3) [52]. CRNDE overexpression has been 
associated with high cell proliferation, migration, and invasion, which corresponds 
with the promotion of tumor growth observed in in vivo studies [53]. In addition, 
the expression pattern of RP11-334C17.6 and BTA10 allows to group patients with 
a greater survival from those with worse results, as well as the prognosis of each of 
the four GBM subtypes [52]. Currently, the available data are promising, and based 
on them, specific lncRNAs have been postulated as potential biomarkers for GBM 
diagnosis and prognosis, which with further evidence could be used in the medical 
practice.
3.3 Circulating lncRNAs
It is a fact that the establishment of novel biomarkers for Ast is essential and 
their identification and clinical application by means of less invasive methods 
Table 3. 
LncRNAs as potential GBM biomarkers.
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would be ideal. To date, many studies have demonstrated the usefulness of cir-
culating lncRNAs for diagnosis and prognosis of many diseases, including GBM 
[46, 54, 55]. The profile expression of lncRNAs was determined in blood serum 
of GBM patients and high levels of HOTAIR (HOX transcript antisense RNA) 
and GAS5 [growth arrest specific 5 (nonprotein coding)] were prognostic factors 
to determine patient’s survival and GBM progression [56]. Overexpression of 
circulating HOTAIR has been observed in different types of cancer [57–61], but 
its downregulation was detected in patients with acute myocardial infarction 
[62]. Interestingly, the presence of high levels of circulating HOTAIR DNA was 
also detected in breast cancer (BC) patients, where it has a potential use for BC 
diagnosis [60]. Unlike those observed in the GBM, most studies have shown 
that circulating GAS5 was downexpressed in different types of cancer, which 
allowed the diagnosis of both intraductal papillary mucinous neoplasms [63] 
and nonsmall cell lung cancer [64, 65], as well as BC prognosis [66]. By contrast, 
overexpression of circulating GAS5 could be used to predict treatment response 
in head and neck cancer [67]. According to this, the overexpression of HOTAIR 
observed in all cancer types studied to date strongly suggests a central function 
of this lncRNA in the establishment, maintenance, and/or progression of cancer 
in general. Therefore, it is very important to identify the processes that HOTAIR 
is controlling in cancer in order to postulate molecular tools to eradicate neoplas-
tic cells.
MALAT1 [metastasis associated lung adenocarcinoma transcript 1 (nonprotein 
coding)] was another lncRNA with changes on its circulating expression levels in 
GBM. This lncRNA was overexpressed, and this was associated with poor overall 
survival and with a high GBM recurrence [19]. Overexpression of circulating 
MALAT1 has been observed in many types of cancer and it seems to be useful for 
cancer diagnosis and prognosis [68–73]. On the contrary, Peng et al. [74] showed 
that MALAT1 downregulation in blood was important for early diagnosis in nons-
mall cell lung cancer. Based on the above, the presence of a biomolecule in distinct 
corporal fluids is a noninvasive form at the molecular level either by the presence 
or the absence of a disease, as well as by the patient’s prognosis with an specific 
disease. According to the studies performed to date, the use of circulating lncRNAs 
in the medical practice seems very promising.
3.4 Search for GBM biomarkers from a system biological perspective
Since a biomolecule does not act alone and depends on the cellular context to 
carry out its biological functions, different groups of study have focused on the 
identification of the lncRNA interactome in GBM. Evidence indicates that lncRNAs 
could interact with themselves, as well as with other biomolecules, such as mRNAs, 
miRNAs, and proteins; changes on the lncRNA activity at distinct molecular 
levels could affect their interaction networks and the correct cellular functioning 
[5, 75–77].
Yan et al. [78] established interaction networks between lncRNAs and mRNAs 
aberrantly expressed in GBM, and based on this, they postulated “hub genes” which 
were involved in GBM pathogenesis. Similarly, under this perspective, it was found 
that complexes conformed by lncRNA•mRNA (HOTAIR-MX11-CD58/PRKCE and 
HOTAIR-ATF5-NCAM1) or lncRNA•lncRNA (MCM3AP-AS-MIR17HG) could be 
potential biomarkers for GBM prognosis [79–82]. Importantly, the TP73-AS1•RFX1 
complex (TP73 Antisense RNA 1 and Regulatory Factor X1, respectively) was 
identified as an important factor for the control of apoptosis in this type of tumor 
[83]. To sum up, the cancer study from a system biological perspective has allowed 
to identify the complex interaction networks where many biomolecules are involved 
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to regulate specific cellular processes; alterations in the operation of any of these 
components will affect the correct functioning of the cell. Specifically, lncRNA 
changes could lead to an amplification of the aberrant signals and this could be 
more significant if the lncRNAs interact with other ncRNAs, given that they have 
many targets of regulation.
3.5 Radio and chemoresistance
A major clinical problem is the resistance to chemotherapy and radiotherapy; 
therefore, identification of “molecular tools” that can predict and in the best-case 
scenario, improve the cellular response to these treatments would be ideal. Wang 
et al. [80] established a prediction model for radiosensitivity by detecting differen-
tial expressed lncRNAs and mRNAs after irradiation. Interestingly, the algorithm 
differentiated those patients that were radiosensitive and with a greater survival, 
from the patients with radioresistance; unfortunately, as far as we know, this is the 
only study focused on GBM radioresistance.
In addition, the involvement of lncRNAs in chemoresistance has been widely 
studied. LncRNAs RP11-838 N2.4 [84] and MALAT1 [19, 55] were shown to be 
associated with TMZ resistance (Table 3). Hiseq sequencing identified the profile 
expression of lncRNAs, which was specific and differentiated patient resistant to 
TMZ from those sensitive to this drug. This analysis showed that overexpression 
of MALAT1 and its circulating form was related to a lower response to chemo-
therapy and to a shorter survival time of patients with GBM by controlling the 
miR-203 and TYMS (thymidylate synthase) levels, which was tested in TMZ 
resistant GBM cells [19]. Another fact worthy of mention is that other components 
of the MALAT1 interactome have been elucidated to be important for TMZ resis-
tance. MALAT1 overexpression maintained high levels of expression of specific 
genes, such as ABCB1 (ATP binding cassette subfamily B member 1), ABCC5 
(ATP binding cassette subfamily C member 5), LRP1 (LDL receptor related 
protein 1), and ZEB1 (zinc finger E-box binding homeobox). Notably, forced 
decrease of MALAT1 resulted in TMZ sensitization by decreasing the levels of 
ZEB1 [55]. Meanwhile, alterations in the axis RP11-838 N2.4•miR-10•EphA8 (EPH 
Receptor A8) were also involved in GBM cell resistance to TMZ [21]. All these 
facts supported the importance of the study of lncRNAs for clinical purposes and 
specifically gain knowledge regarding the prognosis of patients to radiotherapy or 
chemotherapy.
3.6 LncRNAs in stem cells
Many lines of evidence have shown the involvement of lncRNAs in the control 
of many cellular processes in cancer stem cells (CSCs) [85–87], but their par-
ticipation in Ast has been very poorly studied. These cells are able to self-renew 
and differentiate into diverse cancer cell lineages to form tumors, so CSCs have 
been proposed as potential targets for cancer treatment. To further understand 
this, Balci et al. [88] determined the profile expression of lncRNAs in GBM stem 
cells (GSCs) relative to control stem cells. From these differentially expressed 
lncRNAs, PCAT-1 (prostate cancer associated transcript 1 (nonprotein coding)), 
MEG3 (maternally expressed 3 (nonprotein coding)), and HOTAIR functioned 
as tumor suppressors in GBM. This was related to alterations in gene expression. 
Interestingly, another study identified that even identical GSCs showed varia-
tions in their expression profile of lncRNAs, as well as in the variants produced 
by specific subgroups of cells. Despite this, the authors could establish a stem cell 
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signature of 31 lncRNAs according to their expression levels [57]. Meanwhile, in 
hypoxic conditions, the expression of the lncRNA HIF1A-AS2 (hypoxia inducible 
factor 1 alpha-antisense RNA 2) was induced and this led to positive control of the 
growth, self-renewal, and molecular reprograming of the GSCs [20]. Significantly, 
the control of these cellular processes was possible by regulating an interaction 
network, which will be described later.
Although many studies have focused on studying the changes on the expres-
sion of lncRNAs, very few have attempted to determine the mechanisms underly-
ing this deregulation. In this sense, Zhang et al. [89] showed a feedback loop 
which controlled the expression of the lncRNA FOXM1-AS (Forkhead box M1 
antisense) and it proved to be important for GSC tumorigenesis. ALKBH5 (AlkB 
homolog 5, RNA demethylase) is a demethylase highly expressed in GBM GSCs, 
which was associated with an enhanced self-renewal and tumorigenesis of these 
cells. These malignant cell processes were controlled by FOXM1 (Forkhead box 
M1) and FOXM1-AS, which increased their expression levels by a greater demeth-
ylation of the immature transcripts of FOXM1. In this pathway of regulation, 
FOXM1-AS was important to facilitate the action of ALKBH5 on the nascent tran-
scripts of FOXM1; therefore, a therapy in which the action of this lncRNA was 
reduced or blocked could be important to prevent GBM tumorigenesis. Taken 
together, these studies showed that although expression changes of lncRNAs 
were useful for GBM diagnosis and prognosis, they necessarily not represent 
the entire tumor, but rather this seems to associate with certain subgroups of 
cells that predominate over others and express particular lncRNAs. Therefore, 
the applicability of a differentially expressed biomolecule in the medical prac-
tice—particularly lncRNAs—must be done with caution and with all the required 
evidence.
4. Action mechanisms of lncRNAs in GBM
In addition to expression changes, it is necessary for the elucidation of the action 
mechanisms by which lncRNAs are acting. Evidence showed that lncRNAs act at 
both cytoplasmic and nuclear levels and that this is done directly and/or by their 
interaction with protein complexes and/or with other lncRNAs or different RNA 
species, such as mRNAs and miRNAs [5, 75–77]. Also, lncRNAs can regulate many 
signaling pathways by controlling the cytoplasmic disposal of mRNAs and miRNAs 
and even by producing small RNA species, such as miRNAs [89].
4.1 Sponge lncRNAs
This class of lncRNAs regulates miRNA disposal in the cell cytoplasm by cap-
turing them and blocking their action [90, 91]. To date, all lncRNAs identified as 
“sponges” in the GBM acting as suppressors and involved in lncRNA upregula-
tion and miRNA attenuation were associated with GBM Table 4). LncRNAs H19 
(imprinted maternally expressed transcript (nonprotein coding)) and NEAT1 
(nuclear paraspeckle assembly transcript 1 (nonprotein coding)) controlled the 
action of the miRNA let-7e, whose levels were downregulated in GBM due to the 
overexpression of these lncRNAs [92, 93]. Specifically, the axis H19•let-7e was 
involved in maintaining the phenotype of stem cells, which was associated with 
tumor malignancy and TMZ chemoresistance [93]. Similarly, a low disposal of 
let-7e by NEAT1 overexpression, resulted in a higher activity of its mRNA target 
NRAS (NRAS proto-oncogene, GTPase), which leads to GBM malignancy [92]. 
Primary Intracranial Tumors
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Other lncRNAs that function as sponges in GBM were related to tumor malignancy. 
For example, the upregulation of XIST (X inactive specific transcript (nonprotein 
coding)) was related to GSC malignancy, tumor growth, and poor mice survival by 
controlling the action of miR-152 [94]. Meanwhile, the attenuation of the miR-299 
disposal was controlled by the overexpression of TUG1 (lncRNA taurine upregu-
lated 1), which was related to tumor malignancy by the overactivation of VEGFA 
(vascular endothelial growth factor A) [95] and apoptosis evasion [93].
Similarly, GBM malignancy was mediated by the overexpression of RP11-
838N2.4 and SNHG7 (small nucleolar RNA host gene 7), which regulated the 
function of miR-10 and miR-5095, respectively. In the first case, the attenuation of 
the action of miR-10 was associated with apoptosis evasion, and the reestablish-
ment of the axis RP11-838 N2.4•miR-10•EphA8 (EPH receptor A8) induced this 
programmed cell death [21]. Meanwhile, reestablishment of the SNGH7•miR-
5095•CTNNB1 (catenin beta 1) axis arrested tumor growth and decreased metasta-
sis by decreasing the expression of CTNNB1, which is involved in the Wnt/β-catenin 
pathway [96]. Finally, it was observed that GBM proliferation, migration, and 
invasion were also promoted by the overexpression of CRNDE and the consequent 
attenuation of the miR-136-5p expression; all these led to the overactivation of 
BCL2 and WNT2, which are target genes of this miRNA [97]. According to the 
LNCipedia compendium, there are many variants reported for these lncRNAs; 
therefore, it would be very interesting and important to identify which lncRNA 
“Sponges” 
LncRNAs
microRNA mRNA target Cellular process altered Signaling 
pathway
Tumor suppressors
H19
NEAT1
Let-7e NRAS (NRAS Proto-
Oncogene, GTPase)
H19: stem cells phenotype
NEAT1:
XIST miR-152 Proliferation, migration, 
invasion, apoptosis 
evasion, tumor growth 
and poor mice survival
TUG1 miR-299 VEGFA (Vascular 
Endothelial Growth 
Factor A)
Angiogenesis induction
RP11-838N2.4 miR-10 EphA8 (EPH Receptor 
A8)
Apoptosis evasion Apoptosis
SNHG7 miR-5095 CTNNB1 (Catenin Beta 
1)
Proliferation, migration, 
invasion, apoptosis 
evasion
Wnt/β 
catenin
MALAT1 miR-203 TYMS (Thymidylate 
Synthetase)
Low chemotherapy 
response
Shorter survival time of 
patients
CRNDE miR-136-5p Wnt2 (Wnt Family 
Member A2)
BCL2 (BCL2 Apoptosis 
Regulator)
Apoptosis evasion Wnt
Apoptosis
CASC2 miR-101 CPEB1 (Cytoplasmic 
Polyadenylation Element 
Binding Protein 1)
Cell proliferation
Tumorigenesis
Table 4. 
LncRNAs as sponges in adult GBM.
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variants are expressed in GBM and which of them have the binding sites for trap-
ping these miRNAs. Also, further studies are necessary to know if H19 and NEAT1 
regulate the action of let-7e in a synergistic manner.
A very interesting case was that of the lncRNA CASC2c (cancer susceptibility 
candidate 2; formerly C10orf5). Besides its interaction with miR-101, this lncRNA 
was involved in the processing of the pre-miR-101 into mature miR-101 and 
competed with this miRNA for the mRNA CPEB1 (cytoplasmic polyadenylation 
element binding protein 1). High levels of CASC2c and consequently a reduced 
activity of the axis miR-101•CPEB1 were associated with a high cell proliferation 
and tumorigenesis. Therefore, a decrease in CASC2c expression and an increased 
disposal of miR-101 were related to better patient’s prognosis [98]. This evidence is 
an indication of all biological functions that an lncRNA can play in the cell and how 
the system ensures the regulation of gene expression by regulating at different levels 
the biogenesis of miRNAs (Figure 3). In consequence, if something modifies the 
processing of the pre-miR-101 or affects the regulation of its mature form, CASC2c 
would try to compensate the miRNA action by competing for its target genes. 
Evidently, other mechanisms must be involved in the biogenesis of this miRNA.
4.2 By interacting with mRNAs
Besides the lncRNA interaction with miRNAs, there is evidence indicating that 
lncRNAs can carry out their biological functions when they interact with mRNAs 
and/or proteins [5, 75–77]. As mentioned above, HIF1A-AS2 was involved in the 
GSC malignancy under hypoxia conditions. The action of this lncRNA was per-
formed in part by directly interacting with IGF2BP2 (insulin-like growth factor 
2 MRNA binding protein 2) and DHX9 (DExH-box helicase 9), which finally 
controlled the action of HMGA1 (high mobility group AT-Hook 1) [20]. According 
to this, elucidation of all the components that formed the interactome network 
of HIF1A-AS2 in the GSCs would be crucial to establish molecular tools for GBM 
treatment.
Figure 3. 
The lncRNA CASC2 regulated the function of the miR-101 at different molecular levels. CASC2 was involved 
in the processing of the pre-miR-101 and also interact with its mature form to regulate the function of this 
miRNA. If any of these mechanisms fail, CASC2 ensures the miR-101 regulation by interacting with its mRNA 
targets.
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5. Pediatric Ast
Adult and p-Ast are distinct molecular entities and are classified into different 
groups; therefore, studies in pediatric Ast are imperative. The first study performed 
in p-Ast was the one where the overexpression HOTAIR and HOX was detected in 
different pediatric brain tumors, including juvenile pediatric Ast (JPA); however, 
the biological meaning of this was not further studied [99].
We identified in the laboratory the expression profile of lncRNAs in p-Ast of 
WHO grades I–IV, given that the function of lncRNAs in p-Ast has been poorly 
studied. Similar to that observed for adult Ast, p-Ast showed many lncRNAs 
with expression changes relative to the control tissues, among histological grades 
or even in the same histological grade [5]. In addition, it was identified that the 
interaction of many differentially expressed lncRNAs with mRNAs and/or miRNAs 
aberrantly expressed was identified. As explained above, these interactions could 
lead to the amplification of the aberrant signals and to the modification of many 
signaling pathways. According to this, there were several hub lncRNAs in p-Ast 
that in relation to their interactions with mRNAs could be altering pathways such 
as FOXO, chemokine, hedgehog, MAPK, and others (Figure 4). Additionally, hub 
lncRNAs potentially useful to distinguish GBM from the other histopathological 
WHO grades were predicted to control diverse metabolic pathways and signaling 
pathways such as Ras, hippo, apellin, etc. (Figure 4).
The interaction of differentially expressed lncRNAs and miRNAs was shown to 
be a complex network that could be involved in modifications on proteoglycans in 
cancer, fatty acid metabolism, cell cycle, and spliceosome. Notably, data analysis 
revealed the presence of circular lncRNAs (circRNAs) with expression changes in 
p-Ast (Figure 5). According to the interactions of circRNAs with miRNAs, this type 
Figure 4. 
Predicted interaction networks between lncRNAs and mRNAs were predicted to be involved in the control of 
signaling pathways. Data showed hub mRNAs that were analyzed with the KEGG (Kyoto Encyclopedia of 
Genes and Genomes) database. Hub mRNAs were those mRNAs with the highest number of interactions with 
lncRNAs. Data were taken from [5] and analyzed with KEGG.
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of lncRNAs was predicted to be involved in regulating cellular growth, survival, 
migration, invasion, adhesion, among others [5] (Table 5).
The integration of proteome and mirnome, as well as transcriptome data showed 
a convergence of all these biomolecules in the control of common signaling path-
ways, which gave an overview of the action of complex networks in cancer, particu-
larly p-Ast [5, 47]. For example, although it is widely known that the MAPK pathway 
is altered in ~88% of gliomas, these data showed novel molecular components 
involved in this signaling pathway in p-Ast, which also allow to differentiate GBM 
from the other histological grades. The lncRNA GRPEL1-1:1 was aberrantly expressed 
in all p-Ast grades when compared to the control tissues, but it was downregulated in 
WHO grades I–III relative to GBM. It is noteworthy to add, this lncRNA was pre-
dicted to interact with miR-15b-5p, and its expression levels were inversely correlated 
to those of lnc-GRPEL1-1:1 (Figure 6). Other lncRNAs such as TIMM22-1:1, Noc4L-
1:1, and LINC-ROR were predicted to be involved in the MAPK pathway, as well as 
in the Wnt pathway and extracellular matrix interactions [5]. In pediatric GBM, the 
overexpression of linc-Ror could lead to the downregulation of miR-145, since there 
is evidence indicating that linc-Ror sponges to miR-145, which was associated with 
cancer malignancy [100, 101]. According to our model, the linc-Ror•miR-145 axis 
could be increasing the expression of IGFR1 (insulin-like growth factor 1 recep-
tor), c-Myc (MYC proto-oncogene, BHLH transcription factor), and STAT1 (signal 
transducer and activator of transcription 1), which causes a sustained angiogenesis 
and increased cell proliferation; however, this must be tested (Figure 6). In patients 
with glioma, linc-Ror was downregulated and this correlated positively and nega-
tively with the expression of SOX11 (SRY-box 11) and KFL4 (Kruppel-like factor 4), 
respectively [101]. In the GBM cell line U87, in vitro assays showed the involvement of 
this lncRNA in the induction of cell proliferation, CD133 expression, and in the for-
mation of neurospheres [101], which are the factors of tumor malignancy. Similarly, 
linc-Ror was downregulated in p-Ast grades I–III, but it was upregulated in GBM 
relative to control tissues and other p-Ast grades [5]. Therefore, linc-Ror seems to be a 
candidate to function as a biomarker for p-Ast diagnosis and prognosis.
Figure 5. 
Circular lncRNAs in pediatric astrocytoma. Predictions showed differentially expressed circRNAs in pediatric 
astrocytoma, which have many binding sites for miRNAs.
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KEGG pathway p-value Number 
of genes
Number 
of 
miRNAs
Potential cellular processes 
altered
Proteoglycans in 
cancer
8.91e−11 120 14 Cellular growth and survival
Cell migration and invasion
Cell adhesion
Apoptosis
Angiogenesis
Vascular permeability
Fatty acid metabolism 9.64e−09 28 12 Fatty acid metabolism
Adherens junction 3.85e−08 49 12 Actin polymerization
Cell growth and differentiation
Gene expression
Cell cycle 3.85e−08 85 14 Ubiquitin mediated proteolysis
DNA biosynthesis
Origin recognition complex
Mini-Chromosome maintenance
Protein processing 
in the endoplasmic 
reticulum
2.59e−07 101 14 Proteasome
Apoptosis
Fatty acid elongation 1.78e-06 13 7 Fatty acid degradation
Fatty acid biosynthesis
p53 signaling pathway 2.12e−06 50 14 Cell cycle arrest
Apoptosis
Inhibition of angiogenesis and 
metastasis
DNA repair and damage 
prevention
Inhibition of IGF-1/mTOR 
pathway
Exosome mediated secretion
p53 negative feedback
Cellular senescence
Hippo signaling 
pathway
2.29e-06 77 14 Pro-apoptotic genes
Anti-apoptotic genes
Pro-proliferation genes
Cell contact inhibition
Organ size control
Adherens junctions
TGF-beta signaling 
pathway
2.32e−06 48 12 Differentiation, neurogenesis, 
ventral mesoderm specification
Angiogenesis, extracellular matrix 
neogenesis, immunosuppression, 
apoptosis induction.
G1 arrest
Gonadal growth, embryo 
differentiation, placenta formation
Left-right axis determination
Prion diseases 9.44e−06 15 9 Neuronal apoptosis
Autophagy
Oxidative stress
Proliferation of astrocytes
Table 5. 
Pathways potentially regulated by differentially expressed super sponges in pediatric astrocytoma; DIANA 
MirPath V 3.0 analysis.
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6. Conclusions
The lncRNA study in Ast has demonstrated an aberrant expression of this type 
of RNAs in both tumors and blood, which was useful to distinguish Ast from its 
nonneoplastic counterpart. The elucidation of molecular signatures from circulat-
ing lncRNAs is very promising due to their potential use as noninvasive tools for 
the diagnosis and prognosis of Ast. From another approach, it could be relevant 
the identification of complete interaction networks in which lncRNAs, other RNA 
species, and proteins were involved, since this would give a “panoramic vision” of 
how the aberrant system functions in astrocytic tumors. This could be crucial for 
the creation of molecular tools for their treatment.
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